Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent.
ROSANIL ® Cleanser is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.
Published Studies Related to Rosanil (Sulfacetamide / Sulfur)
Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. [2005.06]
Topical metronidazole and combination sodium sulfacetamide and sulfur commonly are used to treat rosacea. Recently, the relative efficacy and safety of sodium sulfacetamide 10% and sulfur 5% cream with sunscreens (Rosac Cream) (n = 75) and metronidazole 0.75% cream (Metrocream) (n = 77) were compared in an investigator-blinded, randomized, parallel-group study at 6 sites...
Clinical Trials Related to Rosanil (Sulfacetamide / Sulfur)
RosaC-RF : Bipolar Radiofrequency vs Doxycycline in Rosacea [Recruiting]
Rosacea is a chronic facial disfiguring dermatosis characterized by different stages like
flushing, erythema, telangiectasia and papulo-pustular lesions. Recommended treatments
include topical (metronidazole) and systemic (doxycycline) antibiotics with only a
suspensive effect. The bipolar radiofrequency (RF) with Elos system (infrared light) is a
device emitting an electromagnetic current inducing an increase in temperature when applied
on the skin, potentiated by infrared light. The monopolar RF has already been used in
rosacea on a small number of cases with positive and prolonged results. RF with Elos system
has been evaluated on erythemato-telangiectasic rosacea with encouraging results. Demodex
folliculorum (DF) is a long transparent mite which asymptomatically parasitizes
pilosebaceous follicle of normal human skin sometimes responsible of inflammatory facial
dermatoses. The prevalence and density of DF are increased in rosacea, and DF is suspected
to play a role in the pathogenesis of rosacea. DF is sensitive to heat, and the
investigators hypothesize that radiofrequency treatment may affect the survival of the mite
and should be effective to treat papulopustular rosacea.
Antidepressants During Pregnancy and Lactation: Pharmacokinetics and Clinical Implications [Recruiting]
Background: The childbearing years are a time of increased vulnerability to the onset of
mood disorders in women and a high prevalence of exposure to antidepressant drugs during
pregnancy and postpartum has been reported. However, the lack of information regarding the
milk transfer and the safety of these drugs in breastfed infants and the related fear of
adverse events for the sucking infant are some of the factors responsible for stopping
prematurely breast-feeding or avoiding drug therapy. Selective serotonin reuptake inhibitors
(SSRI) and selective serotonin and noradrenaline reuptake inhibitors (SNRI) are the most
frequently prescribed antidepressant drugs during pregnancy and the post-partum period. They
exhibit a wide interpatient variability in their concentration profiles that has been
related to numerous environmental, stereochemical, demographic and genetic influences that
might alter the level of exposure of breastfed newborns. Limited information is available
regarding the safety of use of these antidepressant drugs during lactation, and is generally
derived from small studies. A comprehensive description of their distribution and
quantification in milk in a larger cohort of patients under various influences and the
resulting impact on milk concentrations is lacking.
Objectives: The current proposal addresses the primary objectives of quantifying the range
of concentration to citalopram, escitalopram, sertraline, fluoxetine, paroxetine,
fluvoxamine, duloxetine and venlafaxine in mother plasma and breast milk in relation to
genetic polymorphisms, stereochemistry, demographics and environmental factors in a large
cohort of depressive mothers. This will enable to derive the exposure to the breast-fed
child taking into account this variability and therefore better adjust treatment to
potential influences. As secondary objectives, we will examine the neurodevelopmental
outcome of a sub-set of infants subjected to SSRI/SNRI in utero and/or during breastfeeding
at birth, 6, 18 and 36 months, and compared to that of a control population of infants not
subjected to this treatment.
Expected Results: The proposed strategy will offer new information regarding the expected
level of drug exposure associated with each or with a combination of risk factors and help
for optimizing the security and rationalizing the use of antidepressant treatment in
lactating women. Hence, research on the safety of use of these drugs for the developing
child is an area of great public health significance.
Page last updated: 2006-01-31